MedTrace Logo

Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV)

NCT04812496 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-03-25

No results posted yet for this study

Summary

Although several therapeutic agents have been suggested for the treatment of the disease caused by the Coronavirus of the year 2019 (COVID-19), no antiviral has yet demonstrated consistent efficacy.

This is an observational study comparing Tenofovir-DF (disoproxil fumarate) (TDF) with Hydroxychloroquine (HCQ) in the treatment of hospitalized patients with COVID-19 with evidence of pulmonary compromise and with supplemental oxygen required.

Conditions

  • Covid19
  • SARS-CoV Infection
  • Tenofovir

Sponsors & Collaborators

  • Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud

    lead OTHER

Principal Investigators

  • Mario Cornejo-Giraldo, M.D. · Head of the Infectious Diseases Unit

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-05-30
Completion
2021-01-15

Countries

  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812496 on ClinicalTrials.gov